Bioengineered multifunctional nanomedicine for cancer theranostics: integrating targeted drug delivery, molecular imaging, and precision medicine
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgag131 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Shivangi Dubey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical Engineering, Rajiv Gandhi Institute of Petroleum Technology, Amethi 229304, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Neoplasms, Theranostic Nanomedicine, Precision Medicine, Drug Delivery Systems. Die Arbeit nennt 113 Literaturangaben.
Abstract (Originalsprache)
Objectives
Cancer remains a major global health challenge despite significant advances in diagnosis and treatment. Conventional therapies, including chemotherapy, radiotherapy, and surgery, are frequently constrained by non-specific drug distribution, systemic toxicity, multidrug resistance (MDR), and limitations in early tumor detection. This review aims to critically examine recent advances in nanomedicine for targeted cancer therapy and diagnostic imaging, with particular emphasis on nanocarrier platforms, tumor-targeting strategies, stimuli-responsive drug delivery, and nanoparticle-based imaging.
Methods
A comprehensive review of the recent literature was undertaken to evaluate the application of diverse nanomedicine platforms in oncology. Major nanocarrier systems, including liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and quantum dots, were assessed with respect to their physicochemical properties, drug-loading capacity, controlled-release characteristics, targeting potential, and therapeutic applications. Passive and active targeting approaches, including the enhanced permeability and retention (EPR) effect and ligand-mediated targeting, were examined. The applications of stimuli-responsive nanocarriers triggered by tumor-associated pH, temperature, and enzymatic conditions were also evaluated. In addition, the role of nanomedicine in MRI, CT, PET, and fluorescence imaging was reviewed. Key findings Nanomedicine provides substantial opportunities for improving the precision and efficacy of cancer treatment by enhancing drug stability, bioavailability, tumor accumulation, and controlled drug release while potentially reducing exposure of healthy tissues. Active and passive targeting strategies can improve the selective delivery of therapeutic agents to tumor sites, whereas stimuli-responsive systems offer additional spatial and temporal control over drug release. Nanoparticle-based contrast and imaging agents have demonstrated considerable potential for enhancing imaging sensitivity, facilitating earlier tumor detection, and enabling real-time assessment of therapeutic responses. Importantly, several nanomedicine platforms also show promise in overcoming MDR and improving overall therapeutic efficiency. However, challenges related to nanotoxicity, pharmacokinetics, manufacturing scalability, regulatory requirements, and long-term clinical safety continue to limit widespread clinical translation.
Conclusions
Nanomedicine represents a rapidly advancing and potentially transformative approach to cancer diagnosis and treatment. Integration of targeted drug delivery, stimuli-responsive nanocarriers, advanced imaging, and theranostic strategies may contribute to more precise and personalized oncology. Continued investigation into safety, manufacturing, regulatory standardization, and clinical validation will be essential for translating promising nanomedicine platforms from experimental studies into routine cancer care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Mechanical Engineering, Rajiv Gandhi Institute of Petroleum Technology, Amethi 229304, Uttar Pradesh, India.
- University Centre for Research & Development, Chandigarh University, Mohali 140413, Punjab, India.
- Institute of Bioscience and Technology, Shri Ramswaroop Memorial University, Lucknow, Deva Road, Barabanki 225003, Uttar Pradesh, India.
- Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow 226028, Uttar Pradesh, India.
- Research Cell, Amity University Uttar Pradesh, Lucknow Campus, Lucknow 226028, Uttar Pradesh, India.
ORCID-Profile: Manish Dwivedi
Zitieren
APA
Dubey, S., Prakash, S., Deshwal, R. K., & Dwivedi, M. (2026). Bioengineered multifunctional nanomedicine for cancer theranostics: integrating targeted drug delivery, molecular imaging, and precision medicine. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgag131
Vancouver
Dubey S, Prakash S, Deshwal RK, Dwivedi M. Bioengineered multifunctional nanomedicine for cancer theranostics: integrating targeted drug delivery, molecular imaging, and precision medicine. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgag131
BibTeX
@article{Dubey2026,
author = {Dubey, Shivangi and Prakash, Sneha and Deshwal, Ravi K and Dwivedi, Manish},
title = {Bioengineered multifunctional nanomedicine for cancer theranostics: integrating targeted drug delivery, molecular imaging, and precision medicine},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgag131}
}
EUVIMED